NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: Pharmaceutical Preparations
www.rockwellmed.comRockwell Medical Inc's patent US7857977 for TRIFERIC, a bicarbonate solution used in dialysis treatment and for treating anemia, is set to expire on September 8, 2027. The patent covers a stabilized bicarbonate solution containing ferric pyrophosphate, which provides therapeutic benefits for anemia and iron deficiency while potentially reducing the required dose of erythropoietin. The expiry of this patent may impact Rockwell Medical's intellectual property and product offerings, potentially leading to increased competition in the market for related therapies.
Patent ExpiryThe patent US7816404 for TRIFERIC, held by Rockwell Medical Inc, will expire on April 17, 2029. TRIFERIC, a highly water-soluble ferric pyrophosphate citrate chelate, is used for treating iron deficiency and is characterized by having 2% or less phosphate by weight. This patent is significant for its potential to offer advantageous biocompatibility compared to conventional iron treatments. The expiration of this patent could open the market to generic competitors, impacting Rockwell Medical's revenue from TRIFERIC.
Patent Hurdle